[1]
Carofiglio, F.; Lopalco, A.; Lopedota, A.; Cutrignelli, A.; Nicolotti, O.; Denora, N.; Stefanachi, A.; Leonetti, F. Bcr-Abl Tyrosine Kinase Inhibitors in the treatment of pediatric CML. Int. J. Mol. Sci., 2020, 21(12), 4469.
[http://dx.doi.org/10.3390/ijms21124469] [PMID: 32586039]
[http://dx.doi.org/10.3390/ijms21124469] [PMID: 32586039]
[2]
Chen, M.; Zhu, Y.; Lin, Y.; Tengwang, T.; Zhang, L. Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ Open, 2021, 11(1), e042814.
[http://dx.doi.org/10.1136/bmjopen-2020-042814] [PMID: 33468532]
[http://dx.doi.org/10.1136/bmjopen-2020-042814] [PMID: 33468532]
[3]
Shima, H.; Tokuyama, M.; Tanizawa, A.; Tono, C.; Hamamoto, K.; Muramatsu, H.; Watanabe, A.; Hotta, N.; Ito, M.; Kurosawa, H.; Kato, K.; Tsurusawa, M.; Horibe, K.; Shimada, H. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J. Pediatr., 2011, 159(4), 676-681.
[http://dx.doi.org/10.1016/j.jpeds.2011.03.046] [PMID: 21592517]
[http://dx.doi.org/10.1016/j.jpeds.2011.03.046] [PMID: 21592517]
[4]
Millot, F.; Guilhot, J.; Baruchel, A.; Petit, A.; Leblanc, T.; Bertrand, Y.; Mazingue, F.; Lutz, P.; Vérité, C.; Berthou, C.; Galambrun, C. Nicolas Sirvent; Yacouben, K.; Chastagner, P.; Gandemer, V.; Reguerre, Y.; Couillault, G.; Khalifeh, T.; Rialland, F. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur. J. Cancer, 2014, 50(18), 3206-3211.
[http://dx.doi.org/10.1016/j.ejca.2014.10.007] [PMID: 25459396]
[http://dx.doi.org/10.1016/j.ejca.2014.10.007] [PMID: 25459396]
[5]
Deng, M.; Guan, X.; Wen, X.; Xiao, J.; An, X.; Yu, J. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China. Medicine (Baltimore), 2020, 99(7), e19150.
[http://dx.doi.org/10.1097/MD.0000000000019150] [PMID: 32049841]
[http://dx.doi.org/10.1097/MD.0000000000019150] [PMID: 32049841]
[6]
European Medicines Agency (EMEA). Glivec. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/glivec Accessed 8 April 2021.
[7]
US Food & Drug Administration (FDA). Glivec, Summary of Product Characteristics. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2008/021588s024lbl.pdf Accessed 19 June 2021.
[8]
Berman, E.; Girotra, M.; Cheng, C.; Chanel, S.; Maki, R.; Shelat, M.; Strauss, H.W.; Fleisher, M.; Heller, G.; Farooki, A. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk. Res., 2013, 37(7), 790-794.
[http://dx.doi.org/10.1016/j.leukres.2013.02.005] [PMID: 23473999]
[http://dx.doi.org/10.1016/j.leukres.2013.02.005] [PMID: 23473999]
[9]
Giona, F.; Putti, M.C.; Micalizzi, C.; Menna, G.; Moleti, M.L.; Santoro, N.; Iaria, G.; Ladogana, S.; Burnelli, R.; Consarino, C.; Varotto, S.; Tucci, F.; Messina, C.; Nanni, M.; Diverio, D.; Biondi, A.; Pession, A.; Locatelli, F.; Piciocchi, A.; Gottardi, E.; Saglio, G.; Foà, R. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br. J. Haematol., 2015, 170(3), 398-407.
[http://dx.doi.org/10.1111/bjh.13453] [PMID: 25891192]
[http://dx.doi.org/10.1111/bjh.13453] [PMID: 25891192]
[10]
Biondi, A.; Gandemer, V.; De Lorenzo, P.; Cario, G.; Campbell, M.; Castor, A.; Pieters, R.; Baruchel, A.; Vora, A.; Leoni, V.; Stary, J.; Escherich, G.; Li, C.K.; Cazzaniga, G.; Cavé, H.; Bradtke, J.; Conter, V.; Saha, V.; Schrappe, M.; Grazia Valsecchi, M. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol., 2018, 5(12), e641-e652.
[http://dx.doi.org/10.1016/S2352-3026(18)30173-X] [PMID: 30501871]
[http://dx.doi.org/10.1016/S2352-3026(18)30173-X] [PMID: 30501871]
[11]
Biondi, A.; Schrappe, M.; De Lorenzo, P.; Castor, A.; Lucchini, G.; Gandemer, V.; Pieters, R.; Stary, J.; Escherich, G.; Campbell, M.; Li, C.K.; Vora, A.; Aricò, M.; Röttgers, S.; Saha, V.; Valsecchi, M.G. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol., 2012, 13(9), 936-945.
[http://dx.doi.org/10.1016/S1470-2045(12)70377-7] [PMID: 22898679]
[http://dx.doi.org/10.1016/S1470-2045(12)70377-7] [PMID: 22898679]
[12]
Choeyprasert, W.; Yansomdet, T.; Natesirinilkul, R.; Wejaphikul, K.; Charoenkwan, P. Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr. Int., 2017, 59(3), 286-292.
[http://dx.doi.org/10.1111/ped.13136] [PMID: 27541072]
[http://dx.doi.org/10.1111/ped.13136] [PMID: 27541072]
[13]
European Medicines Agency (EMEA). Sprycel. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/productinformation/sprycel-epar-product-information_en.pdf Accessed 8 April 2021.
[14]
US Food & Drug Administration (FDA). Sprycel, Summary of Product Characteristics. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021986s020lbl.pdf Accessed 19 June 2021.
[15]
Vandyke, K.; Dewar, A.L.; Diamond, P.; Fitter, S.; Schultz, C.G.; Sims, N.A.; Zannettino, A.C. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J. Bone Miner. Res., 2010, 25(8), 1759-1770.
[http://dx.doi.org/10.1002/jbmr.85] [PMID: 20225261]
[http://dx.doi.org/10.1002/jbmr.85] [PMID: 20225261]
[16]
Gore, L.; Kearns, P.R.; de Martino, M.L. Lee; De Souza, C.A.; Bertrand, Y.; Hijiya, N.; Stork, L.C.; Chung, N.G.; Cardos, R.C.; Saikia, T.; Fagioli, F.; Seo, J.J.; Landman-Parker, J.; Lancaster, D.; Place, A.E.; Rabin, K.R.; Sacchi, M.; Swanink, R.; Zwaan, C.M. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J. Clin. Oncol., 2018, 36(13), 1330-1338.
[http://dx.doi.org/10.1200/JCO.2017.75.9597] [PMID: 29498925]
[http://dx.doi.org/10.1200/JCO.2017.75.9597] [PMID: 29498925]
[17]
European Medicines Agency (EMEA). Tasigna. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/productinformation/tasigna-epar-product-information_en.pdf Accessed 8 April 2021.
[18]
Kroschwald, L.M.; Tauer, J.T.; Kroschwald, S.I.; Suttorp, M.; Wiedenfeld, A.; Beissert, S.; Bauer, A.; Rauner, M. Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro. Oncol. Lett., 2019, 18(2), 2102-2108.
[http://dx.doi.org/10.3892/ol.2019.10518] [PMID: 31423283]
[http://dx.doi.org/10.3892/ol.2019.10518] [PMID: 31423283]
[19]
Hijiya, N.; Maschan, A.; Rizzari, C.; Shimada, H.; Dufour, C.; Goto, H.; Kang, H.J.; Guinipero, T.; Karakas, Z.; Bautista, F.; Ducassou, S.; Yoo, K.H.; Zwaan, C.M.; Millot, F.; Patterson, B.; Samis, J.; Aimone, P.; Allepuz, A.; Titorenko, K.; Sosothikul, D. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv., 2021, 5(14), 2925-2934.
[http://dx.doi.org/10.1182/bloodadvances.2020003759] [PMID: 34309636]
[http://dx.doi.org/10.1182/bloodadvances.2020003759] [PMID: 34309636]
[20]
European Medicines Agency (EMEA). Iclusig. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-product-information_en.pdf Accessed 8 April 2021.
[21]
US Food & Drug Administration (FDA). Iclusig. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf Accessed on 8 April 2021
[22]
Millot, F.; Suttorp, M.; Versluys, A.B.; Kalwak, K.; Nelken, B.; Ducassou, S.; Bertrand, Y.; Baruchel, A. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. Eur. J. Cancer, 2020, 136, 107-112.
[http://dx.doi.org/10.1016/j.ejca.2020.05.020] [PMID: 32668374]
[http://dx.doi.org/10.1016/j.ejca.2020.05.020] [PMID: 32668374]
[23]
Rossoff, J.; Huynh, V.; Rau, R.E.; Macy, M.E.; Sulis, M.L.; Schultz, K.R.; Burke, M.J.; Athale, U.; O’Brien, M.M.; Gregory, J.J., Jr; van der Sluis, I.M.; Keller, F.G.; Zwaan, C.M.; Suttorp, M.; Hijiya, N. Experience with ponatinib in paediatric patients with leukaemia. Br. J. Haematol., 2020, 189(2), 363-368.
[http://dx.doi.org/10.1111/bjh.16338] [PMID: 31975387]
[http://dx.doi.org/10.1111/bjh.16338] [PMID: 31975387]
Article Metrics
5